Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference
Individual investors are Palisade Bio, Inc.'s (NASDAQ:PALI) biggest owners and were rewarded after market cap rose by US$70m last week [Yahoo! Finance]
Palisade Bio (NASDAQ:PALI) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations